Johnson & Johnson Stock Attracts Major Investors Ahead of Strategic Shift

Major investors are buying Johnson & Johnson stock as it plans a huge medtech divestiture, sees strong drug sales, and targets over $100 billion in revenue by 2026.

Recent regulatory filings with the U.S. Securities and Exchange Commission reveal a notable trend: major institutional investors are significantly increasing their holdings in Johnson & Johnson. The healthcare giant is approaching a historic revenue milestone this year and is reportedly preparing a multi-billion dollar divestiture within its medical technology segment. This strategic pivot is capturing the focused attention of professional money managers.

Strategic Divestiture and Pipeline Progress

The company's strategic refinement is moving forward alongside its financial targets. Industry reports indicate Johnson & Johnson is preparing documentation for the potential sale of its orthopedics unit, DePuy Synthes. A transaction could be valued at more than $20 billion. Capital unlocked from such a move is expected to be redirected toward higher-growth areas within the broader medtech landscape.

Concurrently, the pharmaceutical core business continues to deliver robust growth. The oncology drug Darzalex recently generated a ten percent sales increase within its division. Furthermore, the new immunology treatment, Icotyde, is on the verge of accessing a new multi-billion dollar market following recent regulatory progress toward approval.

Confidence Amidst a Historic Revenue Target

The recent buying activity from firms like Great Oak Capital and AIA Group coincides with a pivotal period for the company. Management has set an operational sales target for 2026 between $99.5 and $100.5 billion. Achieving this would mark the first time the corporation surpasses the $100 billion threshold.

The company's handling of the "TrumpRx" agreement finalized in January is particularly noteworthy. Although the deal mandates lower U.S. drug prices in exchange for tariff exemptions, the executive team appears confident. CFO Joseph Wolk has stated that the company expects to absorb the financial impact, which amounts to several hundred million dollars, and still exceed original analyst profit expectations. This confidence is reflected in the share price, which has gained approximately 15% since the start of the year and is currently trading just over four percent below its 52-week high.

Wall Street Analysts Revise Targets Upward

The combination of a solid core business and strategic restructuring has prompted positive reactions from market analysts. Several major institutions have updated their assessments in recent days:

• HSBC: "Buy" rating with a $280 price target
• Goldman Sachs: "Buy" rating with a $265 price target
• Morgan Stanley: "Buy" rating with a $262 price target

With a consensus average price target nearing $237, the market is signaling further upside potential for the shares. The preparations for the orthopedics unit separation and the pursuit of the $100 billion revenue mark now stand as the concrete milestones against which management will be measured in the coming quarters.